ISRELC 2024 | Dr. You Lu: Transformative Clinical Research in Adaptive Immuno-Radiotherapy

ISRELC 2024 | Dr. You Lu: Transformative Clinical Research in Adaptive Immuno-Radiotherapy

With the development of immune checkpoint inhibitors (ICIs) and the widespread application of immunotherapy, the treatment paradigm for driver mutation-negative lung cancer has been fundamentally transformed. Multiple studies have demonstrated that radiotherapy (RT) can regulate both local and systemic immune responses, triggering anti-tumor immune effects. As a result, the immunomodulatory properties of RT and its synergistic effects when combined with immunotherapy have garnered significant attention within the medical community.
Dr. Hao Zeng: Advancing Uro-Oncology with Cutting-Edge Technologies and Promoting Standardized Care in Grassroots Settings

Dr. Hao Zeng: Advancing Uro-Oncology with Cutting-Edge Technologies and Promoting Standardized Care in Grassroots Settings

Focusing on global progress while highlighting Chinese innovations, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Uro-Oncology Annual Meeting of the Sichuan Anti-Cancer Association were successfully held in Chengdu, Sichuan. Organized by the Sichuan Anti-Cancer Association and hosted by its Urological and Male Reproductive Tumors Committee in collaboration with the Department of Urology at West China Hospital, Sichuan University, the conference brought together experts to discuss the latest advancements. Following the event, Urology Frontier had the privilege of interviewing the conference’s executive chair, Dr. Hao Zeng, to explore the highlights of the meeting and the key areas for enhancing diagnostic and treatment capabilities for grassroots physicians in uro-oncolog
ASH 2024 | Tianjin Medical University Cancer Institute and Hospital’s lymphoma team Explores Cutting-Edge Research and Clinical Practice in Lymphoma

ASH 2024 | Tianjin Medical University Cancer Institute and Hospital’s lymphoma team Explores Cutting-Edge Research and Clinical Practice in Lymphoma

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7–10, 2024, in San Diego, USA. This prestigious gathering brought together global experts and scholars to discuss the latest advancements in hematology. At this year's conference, the Tianjin Medical University Cancer Institute and Hospital's lymphoma team presented 6 significant research studies. As part of the Hematology Frontier series, Dr. Huilai Zhang, the team leader, connected live from a domestic studio with her team on-site in the United States. Together, they delved into their findings, shared insights, and exchanged perspectives, bridging international and domestic expertise. Below is a detailed summary of their discussions, aimed at providing valuable guidance for clinical practice.
CCHIO 2024 | Dr. Chunxia Su: Comprehensive Management and Research Design of IITs in Lung Cancer

CCHIO 2024 | Dr. Chunxia Su: Comprehensive Management and Research Design of IITs in Lung Cancer

Investigator-initiated trials (IITs) refer to clinical research initiated by investigators, conducted in healthcare institutions, and aimed at studying disease diagnosis, treatment, rehabilitation, prognosis, etiology, prevention, and health maintenance. Unlike industry-sponsored trials, IITs are not intended for drug or medical device registration. In recent years, IITs have become an essential part of clinical research, providing critical data and insights for drug development in China. However, the rapid increase in IITs has underscored the need for enhanced management and standardization.
CCHIO 2024 | Dr. Gang Ding: The Era of “Integration” — Exploring Tumor Rehabilitation and Health Education for a China-Specific Oncology Prevention

CCHIO 2024 | Dr. Gang Ding: The Era of “Integration” — Exploring Tumor Rehabilitation and Health Education for a China-Specific Oncology Prevention

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded successfully on November 17. Following the strategic framework of "collaborative integration" in disciplinary development, the conference established dedicated sessions on tumor rehabilitation, health education, cancer prevention, and screening. These sessions offered comprehensive and multidimensional insights into new perspectives, technologies, and concepts for the full-cycle management of oncology, spanning prevention, screening, diagnosis, treatment, and rehabilitation.

Dr. Zhaochong Zeng: Advancing Liver Cancer Care with Targeted Radiotherapy Strategies and Dual MDT Approaches

China bears a significant burden of liver cancer. To prevent its onset and progression, the country, society, and countless physicians have undertaken extensive measures under the framework of "three-level prevention," achieving remarkable progress. With the increasing proportion of early diagnosis and treatment of liver cancer in recent years, a key focus for radiotherapy specialists has been how to precisely select appropriate radiotherapy methods for early-stage liver cancer patients to improve their prognosis. Oncology Frontier interviewed Dr. Zhaochong Zeng from Zhongshan Hospital, Fudan University, to discuss liver cancer prevention and control in China, explore strategies and advantages of proton therapy, brachytherapy, and combined radiotherapy with interventional treatments for early-stage liver cancer, and outline the role of the radiotherapy department in multidisciplinary team (MDT) development for liver cancer.
CCHIO 2024 | Dr. Hong Liu: New Perspectives on Breast Cancer Rehabilitation – The Importance of Psychological Well-being and Multidisciplinary

CCHIO 2024 | Dr. Hong Liu: New Perspectives on Breast Cancer Rehabilitation – The Importance of Psychological Well-being and Multidisciplinary

Breast cancer not only threatens patients' lives but also imposes a heavy psychological burden on women. As the number of breast cancer cases continues to rise, its rehabilitation is gaining increasing attention from society. How to effectively promote comprehensive recovery for breast cancer patients has become an important issue in the medical field. During the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Hong Liu, Chair of the Breast Cancer Integrated Rehabilitation Committee of the Chinese Anti-Cancer Association and a leading expert at Tianjin Medical University Cancer Institute and Hospital. Professor Liu discussed the importance of psychological rehabilitation for breast cancer patients, prospects for the development of the rehabilitation field, applications of new technologies and methods, and the significance of multidisciplinary collaboration. Drawing on her extensive clinical experience, Professor Liu shed light on new trends in breast cancer rehabilitation, offering hope for patients.
The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024. As one of the most influential platforms for scientific communication in hematology, this global event attracted over 25,000 professionals, including clinicians, researchers, and healthcare leaders from more than 100 countries. The conference covered all aspects of malignant and non-malignant hematology, from cutting-edge research to clinical practice and therapeutic innovation, reflecting the latest advancements and future trends in the field.
Dr. Hua You: Development and Validation of an OS Prediction Model for HIV-Infected Liver Cancer Patients

Dr. Hua You: Development and Validation of an OS Prediction Model for HIV-Infected Liver Cancer Patients

Individuals living with HIV are at a higher risk of developing hepatocellular carcinoma (HCC) due to immune system impairment and often face poorer prognoses. At the ongoing 2024 IDWeek Conference, Dr. Hua You from the Children’s Hospital of Chongqing Medical University presented a groundbreaking study on the development of the first-ever prognostic model tailored for HIV-infected HCC patients—the HIHP model. Demonstrating remarkable performance in both internal and external validation, this model offers promising new directions for the treatment and prognosis of HIV-infected HCC patients.